Next Article in Journal
Lack of Toxicity in a Patient with Germline Tp53 Mutation Treated with Radiotherapy
Previous Article in Journal
Metabolic Syndrome–Related Hepatocellular Carcinoma Treated by Volumetric Modulated Arc Therapy
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Current Oncology
Volume 21
Issue 2
10.3747/co.21.1803
curroncol-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

fdg-pet in Two Cases of Neurofibromatosis Type 1 and Atypical Malignancies

by
P. de Blank
1,*,
K. Cole
2,3,
L. Kersun
2,3,
A. Green
2,3,
J.J. Wilkes
2,3,
J. Belasco
2,3,
R. Bagatell
2,3,
L.C. Bailey
2,3 and
M.J. Fisher
2,3
1
Department of Pediatrics, Division of Pediatric Hematology and Oncology, Rainbow Babies and Children’s Hospital, Clevelan, OH 44106, USA
2
Division of Oncology and Center for Childhood Cancer Research, The Children’s Hospital of Philadelphia, Philadelphia, PA 19104, USA
3
Department of Pediatrics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2014, 21(2), 345-348; https://doi.org/10.3747/co.21.1803
Submission received: 2 January 2014 / Revised: 6 February 2014 / Accepted: 4 March 2014 / Published: 1 April 2014

Abstract

Patients with neurofibromatosis type 1 (NF1) are at increased risk for both benign and malignant tumours, and distinguishing the malignant potential of an individual tumour is a common clinical problem in these patients. Here, we review two cases of uncommon malignancies (Hodgkin lymphoma and mediastinal germ-cell tumour) in patients with nf1. Although 18F-fluorodeoxyglucose positron-emission tomography (FDG-PET) has been used to differentiate benign neurofibromas from malignant peripheral nerve sheath tumours, FDG-PET characteristics for more rare tumours have been poorly described in children with NF1. Here, we report the role of PET imaging in clinical decision-making in each case. In NF1, FDG-PET might be useful in the clinical management of unusual tumour presentations and might help to provide information about the malignant potential of uncommon tumours.
Keywords: neurofibromatosis type 1; pediatric oncology; Hodgkin lymphoma; germ-cell tumours; Klinefelter syndrome neurofibromatosis type 1; pediatric oncology; Hodgkin lymphoma; germ-cell tumours; Klinefelter syndrome

Share and Cite

MDPI and ACS Style

de Blank, P.; Cole, K.; Kersun, L.; Green, A.; Wilkes, J.J.; Belasco, J.; Bagatell, R.; Bailey, L.C.; Fisher, M.J. fdg-pet in Two Cases of Neurofibromatosis Type 1 and Atypical Malignancies. Curr. Oncol. 2014, 21, 345-348. https://doi.org/10.3747/co.21.1803

AMA Style

de Blank P, Cole K, Kersun L, Green A, Wilkes JJ, Belasco J, Bagatell R, Bailey LC, Fisher MJ. fdg-pet in Two Cases of Neurofibromatosis Type 1 and Atypical Malignancies. Current Oncology. 2014; 21(2):345-348. https://doi.org/10.3747/co.21.1803

Chicago/Turabian Style

de Blank, P., K. Cole, L. Kersun, A. Green, J.J. Wilkes, J. Belasco, R. Bagatell, L.C. Bailey, and M.J. Fisher. 2014. "fdg-pet in Two Cases of Neurofibromatosis Type 1 and Atypical Malignancies" Current Oncology 21, no. 2: 345-348. https://doi.org/10.3747/co.21.1803

APA Style

de Blank, P., Cole, K., Kersun, L., Green, A., Wilkes, J. J., Belasco, J., Bagatell, R., Bailey, L. C., & Fisher, M. J. (2014). fdg-pet in Two Cases of Neurofibromatosis Type 1 and Atypical Malignancies. Current Oncology, 21(2), 345-348. https://doi.org/10.3747/co.21.1803

Article Metrics

Back to TopTop